Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio as Predictors for Adverse Events in EVAR

April 27, 2021 updated by: Elena Arnaoutoglou, University of Thessaly

Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio as Predictors for Adverse Events in Endovascular Aneurysm Repair for Abdominal Aorticaneurysm

This study investigated the association of chronic inflammatory markers with the clinical outcome after endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study included 230 consecutive AAA patients, treated electively by EVAR from March 2016 to February 2019. The values of simple inflammatory markers,neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), were measured pre- and postoperatively.Adverse events included any major adverse cardiovascular events (MACE), acute kidney injury and death from any cause.

Study Type

Observational

Enrollment (Actual)

230

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Greece
    • Thessaly
      • Larissa, Thessaly, Greece, 41110
        • Univeristy of Thessaly

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study included consecutive AAA patients treated electively by EVAR

Description

Inclusion Criteria:

  • AAA
  • Elective
  • EVAR

Exclusion Criteria:

  • Emergency
  • Open surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
EVAR
Patinets with AAA, treated electively by EVAR. The values of simple inflammatory markers,neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), were measured pre- and postoperatively. Adverse events included any major adverse cardiovascular events (MACE), acute kidney injury and death from any cause
Other: NLR
neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)
Other Names:
  • PLR

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
NLR major cardiovascular events (MACE)
Time Frame: Day 4 postopertively
NLR indicator for major cardiovascular events (MACE)
Day 4 postopertively
PLR major cardiovascular events (MACE)
Time Frame: Day 4 postopertively
PLR indicator for major cardiovascular events (MACE)
Day 4 postopertively
NLR acute kidney injury (AKI)
Time Frame: Day 4 postopertively
NLR indicator for acute kidney injury (AKI)
Day 4 postopertively
PLR acute kidney injury (AKI)
Time Frame: Day 4 postopertively
PLR indicator for acute kidney injury (AKI)
Day 4 postopertively
NLR death
Time Frame: Day 4 postopertively
NLR indicator for death
Day 4 postopertively
PLR death
Time Frame: Day 4 postopertively
PLR indicator for death
Day 4 postopertively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Thessaly

Investigators

  • Principal Investigator: Maria Ntalouka, MD, University Hospital of Larissa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2016

Primary Completion (Actual)

February 1, 2019

Study Completion (Actual)

November 1, 2019

Study Registration Dates

First Submitted

January 5, 2020

First Submitted That Met QC Criteria

February 2, 2020

First Posted (Actual)

February 5, 2020

Study Record Updates

Last Update Posted (Actual)

April 28, 2021

Last Update Submitted That Met QC Criteria

April 27, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NLR, PLR in EVAR

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammation in EVAR

Clinical Trials on NLR

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe